Insider · CIK 0001825983
Abel De La Rosa
Files at DWTX (Dogwood Therapeutics, Inc.). First filing -, latest -.
Abel De La Rosa files SEC Form 4 as director at DWTX (Dogwood Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Abel De La Rosa has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +16,800 | $0.00 | $0 | 16,800 | Jun 17, 2026 |
| Jun 27, 2025 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +2,362 | $0.00 | $0 | 2,362 | Jul 1, 2025 |
| Jun 18, 2025 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 210 | Jun 23, 2025 |
| Jun 18, 2025 | DWTX Dogwood Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +210 | $0.00 | $0 | 420 | Jun 23, 2025 |
Questions about Abel De La Rosa
Answered from the filings on this page, as of the latest one.
Is Abel De La Rosa buying or selling?
Abel De La Rosa has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Abel De La Rosa's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Abel De La Rosa has 0.
Where does Abel De La Rosa file Form 4?
Abel De La Rosa has filed Form 4 at DWTX (Dogwood Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.